While Candel Therapeutics Inc has overperformed by 10.67%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CADL fell by -25.92%, with highs and lows ranging from $14.60 to $3.79, whereas the simple moving average jumped by 1.08% in the last 200 days.
On June 30, 2025, H.C. Wainwright started tracking Candel Therapeutics Inc (NASDAQ: CADL) recommending Buy. A report published by Citigroup on February 20, 2025, Initiated its previous ‘Buy’ rating for CADL. Canaccord Genuity also rated CADL shares as ‘Buy’, setting a target price of $20 on the company’s shares in an initiating report dated February 19, 2025. BofA Securities Initiated an Buy rating on February 07, 2025, and assigned a price target of $15. H.C. Wainwright initiated its ‘Buy’ rating for CADL, as published in its report on December 02, 2022. BMO Capital Markets’s report from November 19, 2021 suggests a price prediction of $18 for CADL shares, giving the stock a ‘Outperform’ rating. UBS also rated the stock as ‘Buy’.
Analysis of Candel Therapeutics Inc (CADL)
To gain a thorough understanding of Candel Therapeutics Inc’s future performance, several well-rounded types of analysis and research techniques can be used, with equity being among the most crucial. The goal here is to ensure that your current return on equity of -98.14% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.64, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
It is also very valuable to look at average volume as an indicator of volatility for a stock, and CADL is recording an average volume of 959.15K. On a monthly basis, the volatility of the stock is set at 6.84%, whereas on a weekly basis, it is put at 9.80%, with a gain of 28.86% over the past seven days. Furthermore, long-term investors anticipate a median target price of $22.00, showing growth from the present price of $6.43, which can serve as yet another indication of whether CADL is worth investing in or should be passed over.
How Do You Analyze Candel Therapeutics Inc Shares?
The number of employees owning shares of the company should also be considered in addition to the fundamentals. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 31.18%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 36.00% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
